Because SMARCB1-deficient sinonasal carcinoma is progressive and has a poor prognosis, it is necessary to develop targeted therapeutics against SMARCB1-associated molecular abnormalities. Here, SMARCB1 is linked to nasal cavity and paranasal sinus carcinoma.